Статті в журналах з теми "Janssen effect"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Janssen effect".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Thorens, Louison, Knut Jørgen Måløy, Mickaël Bourgoin, and Stéphane Santucci. "Taming the Janssen effect." EPJ Web of Conferences 249 (2021): 08004. http://dx.doi.org/10.1051/epjconf/202124908004.
Повний текст джерелаMaksuwan, Atirat. "Janssen’s Effect in Mechanical Behavior and Fracture of Granular Materials." Materials Science Forum 883 (January 2017): 7–11. http://dx.doi.org/10.4028/www.scientific.net/msf.883.7.
Повний текст джерелаNurmohamed, M. T., I. Van der Horst-Bruinsma, A. W. Van Kuijk, S. Siebert, P. Bergmans, K. De Vlam, E. Gremese, et al. "SAT0432 EFFECT OF SEX ON DISEASE CHARACTERISTICS AND DISEASE IMPACT IN PATIENTS WITH PSORIATIC ARTHRITIS (PsA): INSIGHTS FROM THE REAL-WORLD, OBSERVATIONAL MULTINATIONAL PsABio COHORT." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1171.1–1173. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2771.
Повний текст джерелаSaint-Michel, Brice, Marc Georgelin, Sylvain Deville, and Alain Pocheau. "Wall friction and Janssen effect in the solidification of suspensions." Soft Matter 14, no. 46 (2018): 9498–510. http://dx.doi.org/10.1039/c8sm01572d.
Повний текст джерелаHelliwell, P., P. Rahman, A. Deodhar, A. Kollmeier, E. C. Hsia, B. Zhou, X. Lin, C. Han, and P. J. Mease. "SAT0421 GUSELKUMAB DEMONSTRATED AN INDEPENDENT TREATMENT EFFECT ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PHASE-3 TRIALS DISCOVER 1 & 2." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1164.2–1164. http://dx.doi.org/10.1136/annrheumdis-2020-eular.401.
Повний текст джерелаMease, P. J., X. Baraliakos, V. Chandran, E. Soriano, P. Nash, A. Deodhar, E. Rampakakis, et al. "AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 1782–83. http://dx.doi.org/10.1136/annrheumdis-2023-eular.642.
Повний текст джерелаGossec, L., S. Siebert, P. Bergmans, K. De Vlam, E. Gremese, B. Joven-Ibáñez, T. Korotaeva, et al. "SAT0398 PERSISTENCE OF USTEKINUMAB (UST) OR TNF INHIBITOR (TNFI) TREATMENT IN PSORIATIC ARTHRITIS (PsA): INSIGHTS FROM THE LARGE, PROSPECTIVE, MULTINATIONAL, REAL-WORLD PsABio COHORT." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1149–50. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2127.
Повний текст джерелаNash, P., I. McInnes, C. T. Ritchlin, W. C. Tsai, Y. Y. Leung, L. S. Tam, D. Furtner, et al. "AB0525 GUSELKUMAB TREATMENT SHOWS RAPID ONSET OF EFFECT ON COMPONENTS OF AMERICAN COLLEGE OF RHEUMATOLOGY RESPONSE CRITERIA: RESULTS OF 2 RANDOMIZED PHASE 3 TRIALS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1290–91. http://dx.doi.org/10.1136/annrheumdis-2021-eular.434.
Повний текст джерелаGoupille, P., F. Behrens, L. C. Coates, J. Gratacos-Masmitja, P. J. Mease, D. D. Gladman, P. Nash, et al. "POS1044 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB ON ACR CORE COMPONENTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE EXCEED STUDY." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 797–98. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1562.
Повний текст джерелаSchett, G., W. Chen, S. Gao, S. D. Chakravarty, M. Shawi, F. Lavie, E. Theander, M. Neuhold, L. Coates, and S. Siebert. "POS0308 EFFECT OF GUSELKUMAB ON SERUM BIOMARKERS IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE COSMOS STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 403.2–404. http://dx.doi.org/10.1136/annrheumdis-2022-eular.736.
Повний текст джерелаMease, P. J., E. Soriano, S. D. Chakravarty, E. Rampakakis, M. Shawi, P. Nash, and P. Rahman. "POS1030 PAIN RESPONSE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB IS DRIVEN PREDOMINANTLY BY INFLAMMATION-INDEPENDENT EFFECTS." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 828.1–828. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1384.
Повний текст джерелаOrbai, A. M., L. C. Coates, A. Deodhar, P. Helliwell, C. T. Ritchlin, A. Kollmeier, E. C. Hsia, et al. "POS1029 GUSELKUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENTS IN GENERAL HEALTH OUTCOMES MEASURED WITH PROMIS-29 THROUGH 52 WEEKS: RESULTS FROM THE PHASE 3 DISCOVER-1 TRIAL." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 785–86. http://dx.doi.org/10.1136/annrheumdis-2021-eular.471.
Повний текст джерелаFan, Linda. "Experimental research and numerical simulation based on granary effect." Frontiers in Computing and Intelligent Systems 3, no. 2 (April 13, 2023): 96–98. http://dx.doi.org/10.54097/fcis.v3i2.7523.
Повний текст джерелаSiebert, S., L. Coates, G. Schett, S. P. Raychaudhuri, W. Chen, S. Gao, S. D. Chakravarty, et al. "POS0074 IMMUNOLOGICAL DIFFERENCES BETWEEN PsA PATIENTS WHO ARE TUMOR NECROSIS FACTOR INHIBITOR-NAIVE AND WHO HAVE INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 254.2–255. http://dx.doi.org/10.1136/annrheumdis-2022-eular.892.
Повний текст джерелаMease, P. J., P. Helliwell, D. D. Gladman, D. Poddubnyy, X. Baraliakos, S. D. Chakravarty, A. Kollmeier, et al. "POS1037 EFFECT OF GUSELKUMAB, A SELECTIVE IL-23p19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PsA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 832.2–833. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1691.
Повний текст джерелаRitchlin, C. T., P. J. Mease, W. H. Boehncke, J. Tesser, E. Schiopu, S. D. Chakravarty, A. Kollmeier, et al. "AB0526 SUSTAINED GUSELKUMAB RESPONSE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS THROUGH WEEK 52 OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1291–92. http://dx.doi.org/10.1136/annrheumdis-2021-eular.437.
Повний текст джерелаBaraliakos, X., M. Østergaard, D. Poddubnyy, D. Van der Heijde, A. Deodhar, P. Machado, V. Navarro-Compán, et al. "OP0059 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 38.2–40. http://dx.doi.org/10.1136/annrheumdis-2023-eular.301.
Повний текст джерелаSmolen, J. S., T. Korotaeva, M. Nurmohamed, S. Siebert, P. Bergmans, K. De Vlam, E. Gremese, et al. "AB0530 EFFECT OF SKIN SYMPTOMS ON DISEASE IMPACT IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING THE IL-12/23 INHIBITOR USTEKINUMAB OR TNF INHIBITORS IN THE REAL-WORLD PSABIO STUDY." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1295–96. http://dx.doi.org/10.1136/annrheumdis-2021-eular.767.
Повний текст джерелаNash, P., C. T. Ritchlin, P. Rahman, M. Shawi, E. Rampakakis, Y. Lee, A. Kollmeier, et al. "POS1070 BASELINE DETERMINANTS OF PAIN RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 858.2–859. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1158.
Повний текст джерелаKavanaugh, A., E. Soriano, J. Dutz, C. Selmi, J. Yu, E. Rampakakis, M. Shawi, A. M. Bravo Perdomo, F. Lavie, and L. Coates. "AB1094 GUSELKUMAB EFFECT ON INFLAMMATORY CARDIOVASCULAR (CV) RISK BIOMARKERS, EFFICACY, AND SAFETY IN PSORIATIC ARTHRITIS PATIENTS WITH CV RISK FACTORS: POST-HOC ANALYSIS OF 2 PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 1770–71. http://dx.doi.org/10.1136/annrheumdis-2023-eular.512.
Повний текст джерелаCurtis, J., I. Mcinnes, P. Rahman, W. Tillett, P. J. Mease, A. Kollmeier, E. C. Hsia, et al. "AB0756 GUSELKUMAB IMPROVED WORK PRODUCTIVITY AND DAILY ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1675.1–1675. http://dx.doi.org/10.1136/annrheumdis-2020-eular.428.
Повний текст джерелаBraun, J., R. Blanco, H. Marzo-Ortega, L. S. Gensler, F. Van den Bosch, S. Hall, H. Kameda, et al. "POS0299 EFFECT OF SECUKINUMAB ON RADIOGRAPHIC PROGRESSION AND INFLAMMATION IN SACROILIAC JOINTS AND SPINE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR IMAGING OUTCOMES FROM A PHASE III RANDOMISED TRIAL." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 397–98. http://dx.doi.org/10.1136/annrheumdis-2022-eular.529.
Повний текст джерелаRahman, P., P. Helliwell, A. Deodhar, A. Kollmeier, E. C. Hsia, B. Zhou, X. Lin, C. Han, and P. J. Mease. "POS1048 IN PHASE-3 TRIALS DISCOVER 1 & 2, GUSELKUMAB REDUCED FATIGUE OVER 52 WEEKS IN PATIENTS WITH PSORIATIC ARTHRITIS AND DEMONSTRATED INDEPENDENT TREATMENT EFFECTS ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20)." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 801.1–801. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1686.
Повний текст джерелаOgdie, A., J. F. Merola, P. J. Mease, C. T. Ritchlin, J. U. Scher, D. Chan, S. D. Chakravarty, et al. "AB0887 Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1567.2–1568. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1318.
Повний текст джерелаKöhm, M., T. Rossmanith, A. C. Foldenauer, H. Kellner, U. Kiltz, J. Rech, G. R. Burmester, et al. "POS1059 EFFICACY OF UST IN ACTIVE PsA IS INDEPENDENT FROM CONCOMITANT MTX USE, EVEN IN PATIENTS WITH MORE SEVERE SKIN PSORIASIS: SUBGROUP ANALYSIS FROM A RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 850.2–851. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3929.
Повний текст джерелаO’ Brien, A., M. Hanlon, V. Marzaioli, K. Flynn, S. Wade, D. Veale, and U. Fearon. "POS0411 TARGETING JAK-STAT SIGNALLING ALTERS THE PHENOTYPIC CHARACTERISTICS OF PsA SYNOVIAL FIBROBLASTS IN RESPONSE TO THE JAK/STAT ACTIVATOR ONCOSTATIN M." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 435.1–435. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2528.
Повний текст джерелаSparfel, M. A., S. Derolez, J. Law-Wan, N. Azzopardi, P. Goupille, D. Mulleman, and T. Bejan-Angoulvant. "POS0636 INFLUENCE OF DEMOGRAPHIC AND DISEASE RELATED FACTORS ON EFFICACY OF INFLIXIMAB OR GOLIMUMAB IN RHEUMATOID ARTHRITIS. A META-ANALYSIS ON RANDOMIZED PLACEBO- CONTROLLED TRIALS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 556.1–556. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3565.
Повний текст джерелаNash, P., L. S. Tam, W. C. Tsai, Y. Y. Leung, D. Furtner, S. Sheng, Y. Wang, et al. "POS1044 GUSELKUMAB PROVIDES CONSISTENT AND DURABLE PAIN IMPROVEMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF 2 PHASE 3, RANDOMIZED, CONTROLLED CLINICAL TRIALS." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 839–40. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2030.
Повний текст джерелаBaraliakos, X., D. D. Gladman, S. D. Chakravarty, C. Gong, M. Shawi, E. Rampakakis, M. Kishimoto, E. Soriano, and P. J. Mease. "POS0023 PERFORMANCE OF BASDAI VS. ASDAS IN EVALUATING AXIAL INVOLVEMENT IN PATIENTS WITH PSA TREATED WITH GUSELKUMAB: POOLED ANALYSIS OF TWO PHASE 3 STUDIES." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 217.2–218. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2761.
Повний текст джерелаMerola, J. F., Y. H. Liu, Y. W. Yang, M. Miller, M. Shawi, D. Chan, S. Khattri, L. Savage, W. H. Boehncke, and C. Han. "AB0893 An Analysis of Fatigue in Patients With Psoriatic Disease Utilizing SF-36 Vitality Scores: Results Through Week 24 in Phase 3 Trials of Guselkumab in Patients With Psoriasis and Psoriatic Arthritis." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1573–74. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1514.
Повний текст джерелаMease, P. J., A. Lertratanakul, B. Strober, S. Tsuji, P. Richette, C. Lovan, D. Feng, J. Anderson, and F. Van den Bosch. "POS1032 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 788–89. http://dx.doi.org/10.1136/annrheumdis-2021-eular.564.
Повний текст джерелаNash, P., P. Richette, L. Gossec, A. Marchesoni, C. T. Ritchlin, K. Kato, E. Mcdearmon-Blondell, et al. "POS1035 UPADACITINIB AS MONOTHERAPY AND IN COMBINATION WITH NON-BIOLOGIC DMARDs FOR THE TREATMENT OF PSORIATIC ARTHRITIS: SUBGROUP ANALYSIS FROM TWO PHASE 3 TRIALS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 790.1–790. http://dx.doi.org/10.1136/annrheumdis-2021-eular.662.
Повний текст джерелаSeridi, L., M. Cesaroni, M. J. Loza, J. Schreiter, K. Sweet, Y. Orlovsky, I. Baribaud, et al. "OP0161 ASSOCIATION OF BASELINE CYTOTOXIC GENE EXPRESSION WITH USTEKINUMAB RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 101–2. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2407.
Повний текст джерелаBaraliakos, X., E. Pournara, L. Gossec, H. Marzo-Ortega, P. J. Mease, R. White, E. O’brien, B. Schulz, and L. C. Coates. "POS0930 SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL MANIFESTATIONS: PREDICTORS OF RESPONSE FROM THE DOUBLE-BLIND, RANDOMISED, PHASE 3B MAXIMISE TRIAL." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 728.1–728. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2456.
Повний текст джерелаHelliwell, P., L. C. Coates, F. Van den Bosch, D. D. Gladman, L. Gheyle, M. Trivedi, M. Alani, F. O. Le Brun, R. Besuyen, and P. J. Mease. "POS1038 THE EFFECT OF FILGOTINIB ON ENTHESITIS: 100-WEEK DATA FROM AN OPEN-LABEL EXTENSION STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 792.2–793. http://dx.doi.org/10.1136/annrheumdis-2021-eular.884.
Повний текст джерелаCurtis, J., I. McInnes, P. Rahman, D. D. Gladman, F. Yang, S. Peterson, A. Kollmeier, et al. "AB0881 Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1563.2–1564. http://dx.doi.org/10.1136/annrheumdis-2022-eular.733.
Повний текст джерелаKristensen, L. E., P. C. Taylor, V. Navarro-Compán, M. Magrey, J. C. Cappelleri, A. G. Bushmakin, A. Yndestad, and O. Dina. "AB0750 Back pain and morning stiffness as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1500.1–1500. http://dx.doi.org/10.1136/annrheumdis-2022-eular.28.
Повний текст джерелаKavanaugh, A., X. Baraliakos, S. Gao, W. Chen, K. Sweet, S. D. Chakravarty, Q. Song, M. Shawi, F. Behrens, and P. Rahman. "POS0969 GENETIC AND MOLECULAR DISTINCTIONS BETWEEN AXIAL PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 791.2–792. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1500.
Повний текст джерелаCurtis, J., I. Mcinnes, S. Peterson, P. Agarwal, F. Yang, A. Kollmeier, E. C. Hsia, et al. "POS1026 GUSELKUMAB PROVIDES SUSTAINED IMPROVEMENTS IN WORK PRODUCTIVITY AND NON-WORK ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS THROUGH 1 YEAR OF A PHASE 3 TRIAL." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 782.2–783. http://dx.doi.org/10.1136/annrheumdis-2021-eular.244.
Повний текст джерелаNæss, V., R. T. Fosse, and T. Hofstad. "A possible inhibitory effect on the Shwartzman reaction in the rabbit caused by fentanyl-fluanisone tranquillization." Laboratory Animals 20, no. 4 (October 1, 1986): 304–6. http://dx.doi.org/10.1258/002367786780808776.
Повний текст джерелаCoates, L. C., P. J. Mease, P. Helliwell, F. Van den Bosch, M. Trivedi, M. Alani, F. O. Le Brun, et al. "POS1049 EFFECT OF FILGOTINIB ON PASDAS: DRIVERS OF LOW AND VERY LOW ACTIVITY UP TO WEEK 100." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 801.2–802. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1721.
Повний текст джерелаCurtis, J., I. Mcinnes, D. D. Gladman, F. Yang, S. Peterson, P. Agarwal, A. Kollmeier, et al. "POS1028 PATIENT CHARACTERISTICS & CLINICAL FEATURES ASSOCIATE WITH HEALTH-RELATED QUALITY OF LIFE IN BIO-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH WEEK 24 OF THE DISCOVER-2 STUDY." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 784–85. http://dx.doi.org/10.1136/annrheumdis-2021-eular.432.
Повний текст джерелаMateos, Maria, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hajek, Meletios A. Dimopoulos, et al. "Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study." Blood 136, Supplement 1 (November 5, 2020): 48–50. http://dx.doi.org/10.1182/blood-2020-138391.
Повний текст джерелаDeodhar, A., X. Baraliakos, I. Mcinnes, K. De Vlam, L. Bessette, A. Maniccia, R. Lippe, et al. "POS0907 EFFECT OF UPADACITINIB ON REDUCING PAIN IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND INADEQUATE RESPONSE TO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 712–13. http://dx.doi.org/10.1136/annrheumdis-2021-eular.604.
Повний текст джерелаGladman, D. D., M. Starr, R. Ranza, A. M. Bravo Perdomo, M. Strauss, M. Shawi, C. Han, E. Rampakakis, A. Andrew Östör, and P. J. Mease. "AB1087 LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 1765.1–1765. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1918.
Повний текст джерелаRamiro, S., R. B. M. Landewé, D. Van der Heijde, A. Sepriano, O. Fitzgerald, M. Østergaard, J. Homik, et al. "POS0111 MORE METICULOUSLY FOLLOWING TREAT-TO-TARGET IN RA DOES NOT LEAD TO LESS RADIOGRAPHIC PROGRESSION: A LONGITUDINAL ANALYSIS IN BIODAM." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 279–81. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2161.
Повний текст джерелаKreuter, M., F. Bonella, K. Kathrin, J. Henes, E. Siegert, G. Riemekasten, N. Blank, et al. "POS0834 LONG-TERM OUTCOME OF SSC ASSOCIATED ILD: IMPROVED SURVIVAL IN PPI TREATED PATIENTS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 670.2–671. http://dx.doi.org/10.1136/annrheumdis-2021-eular.878.
Повний текст джерелаBahlis, Nizar J., Shambavi Richard, Darrell J. White, Sebastian Grosicki, Christine Chen, Sosana Delimpasi, Heather J. Sutherland, et al. "Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)." Blood 138, Supplement 1 (November 5, 2021): 1634. http://dx.doi.org/10.1182/blood-2021-146324.
Повний текст джерелаCoates, L., J. Ramírez, D. Mcgonagle, S. Aydin, M. Zimmermann, F. Nantel, M. Shawi, E. Rampakakis, P. Nash, and P. J. Mease. "POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 1137.1–1137. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2581.
Повний текст джерелаCurtis, J., A. Deodhar, E. Soriano, E. Rampakakis, M. Shawi, N. Shiff, M. Strauss, C. Han, W. Tillett, and D. D. Gladman. "AB1084 GUSELKUMAB PROVIDES RAPID CLINICALLY MEANINGFUL IMPROVEMENTS IN CLINICAL AND PATIENT REPORTED OUTCOMES AND SUSTAINED DISEASE CONTROL OF PSORIATIC ARTHRITIS." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 1762–63. http://dx.doi.org/10.1136/annrheumdis-2023-eular.515.
Повний текст джерела